A Power Partnership Pushes Europe’s mRNA Ambitions

Ethris and Thermo Fisher team up to scale stable mRNA innovations and advance the SNIM RNA platform

3 Dec 2025

Europe’s biotech sector is gaining momentum as Ethris, a German RNA developer, forms a strategic partnership with Thermo Fisher Scientific to speed the development of next-generation mRNA medicines. The collaboration aims to combine Ethris’s research platforms with Thermo Fisher’s global manufacturing capabilities, as companies seek to move mRNA beyond its early focus on vaccines.

At the centre of the partnership is Ethris’s SNIM RNA platform, which is designed to support a range of uses, including therapeutic proteins, protein replacement therapies and vaccines. The company says the platform addresses common limits of conventional mRNA, which can degrade quickly in the body and trigger strong immune responses.

Ethris has focused on engineering mRNA sequences intended to remain stable and active for longer periods while maintaining a controlled safety profile. The approach reflects a broader effort in the sector to improve durability and predictability, which are seen as key to expanding mRNA into chronic and repeat-dose treatments.

One of the company’s most advanced programmes, ETH47, targets respiratory disease through nasal delivery. Publicly released data indicate that the therapy stimulates local production of interferon lambda and remains concentrated at the site of delivery, with no measurable systemic exposure. Such findings suggest potential for repeat dosing and site-specific activity, although further clinical data will be required.

Under the agreement, Thermo Fisher will support process development and manufacturing at scale, a step that many early-stage biotechnology companies struggle to achieve on their own. Executives at both groups have said the partnership is intended to shorten the path from laboratory research to clinical studies by pairing innovation with established production systems.

The alliance also reflects wider trends in the biotech industry, where rising development costs, supply chain constraints and regulatory demands are encouraging closer collaboration. While partnerships can reduce independence for smaller developers, they are increasingly viewed as necessary to bring complex therapies to market.

As competition intensifies around delivery methods, stability and manufacturing scale, further deals are expected. The Ethris–Thermo Fisher partnership points to a future in which mRNA technologies play a broader role across medicine, provided technical and regulatory hurdles can be overcome.